• CSE: DTC
  • FSE: DTC
  • OTCQB: DTCFF
  • Download our Corporate Deck
  • Download our Corporate Deck (German)
  • GER
  • ENG
  • FR
Defence Therapeutics
  • About Us
  • Accum Technology
  • Investors
    • Investor Relations
    • 2025 AGM
    • 2025 SEDAR Proxy
  • News
  • Contact
Select Page
Defence To Present New Scientific Data On Its Adc-Enhancing Accum Technology At The World Adc Conference In San Diego, Usa, November 4-5, 2025

Defence To Present New Scientific Data On Its Adc-Enhancing Accum Technology At The World Adc Conference In San Diego, Usa, November 4-5, 2025

by FiveSenses | Oct 23, 2025 | News Release

Montreal, QC, Canada, October 23rd, 2025 – Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce that it will present new scientific data highlighting the...
Defence Therapeutics To Attend Cphi Worldwide In Frankfurt, October 28-30, 2025

Defence Therapeutics To Attend Cphi Worldwide In Frankfurt, October 28-30, 2025

by FiveSenses | Oct 6, 2025 | News Release

Montreal, QC, Canada, October 6th, 2025 – Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce its participation at CPHI Worldwide 2025, taking place in...
Defence Therapeutics Appoints Dr. Mark Lambermon As Head Of Quality And Operations

Defence Therapeutics Appoints Dr. Mark Lambermon As Head Of Quality And Operations

by FiveSenses | Oct 2, 2025 | News Release

Montreal, QC, Canada, October 2nd, 2025 – Defence Therapeutics Inc. (“Defence” or the “Company”), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the appointment of Mark Lambermon, PhD, as Head of Quality and...

Recent Posts

  • Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
  • Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
  • Defence Therapeutics Provides Updates on Sharing Agreement
  • Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
  • Defence Therapeutics Provides Updates on Sharing Agreement

Recent Comments

    Archives

    • October 2026
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • September 2023
    • July 2023
    • June 2023
    • May 2023
    • April 2023

    Categories

    • Communiqué de presse
    • News Release
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Connect with us:
    Sign up for news and investor alerts.

    /* real people should not fill this in and expect good things - do not remove this or risk form bot signups */
    • About Us
    • Technology
    • Pipeline
    • Investor Relations
    • Corporate Presentation (PDF)
    • Press Releases
    • Legal Information
    • Privacy Policy
    • Contact

    Copyright © 2025. Defence Therapeutics. All Rights Reserved.